Health Care
Drug Prices
New Issue Brief: Biopharma Drug Makers Are Not the Most Profitable Players in Health Care
A new issue brief released by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute finds that innovative drug manufacturers earn some of the lowest risk-adjusted returns in the U.S. health care system, despite making the largest investments in research and development. The findings challenge the ...
Commentary
Enhanced Obamacare subsidies are gone. They deserve to stay that way
House Ways and Means Committee Chairman Jason Smith (R-MO) took to the chamber’s floor last week to voice his opposition to legislation that would extend the pandemic-era enhanced premium subsidies for Obamacare plans for three years. Unfortunately, his wise counsel fell on deaf ears, as all Democrats and 17 Republicans ...
Drug Prices
PRI Files Amicus Brief in Major Supreme Court Case That Could Upend Future Medical Innovation Nationwide
SACRAMENTO – California-based free market think tank the Pacific Research Institute announced today that it has filed an amicus curiae brief urging the U.S. Supreme Court to hear two cases challenging the federal government’s new prescription drug pricing program enacted under the Inflation Reduction Act. The cases, Janssen Pharmaceuticals, Inc. ...
Commentary
Congress Must Prioritize Patients, Not Insurers, In Renewed Healthcare Debate
Congress has returned to Washington. Democrats are renewing their call to extend COVID-era health insurance subsidies to shield people from hefty premium increases. Just last week, some Republicans in the House joined them to pass a bill that extends these subsidies—putting the question squarely before the Senate. That approach would ...
Commentary
California should embrace competition to promote better health insurance
Following a depressingly familiar pattern, California is once again undermining health care competition in the vain hope that less competition will lead to lower prices. It won’t. In its latest anti-competitive actions, starting Jan. 1, California’s Department of Health Care Services will be limiting competition for plans (called Medi-Medi plans) ...
Blog
How can we make drugs more affordable without sacrificing future cures?
How can we make drugs more affordable without sacrificing future cures? To a large extent, the current system works fairly well already to make most of the drugs that Americans take affordable. And that’s because of our robust generics market. Around 90% of prescriptions filled each year are for generics ...
Commentary
Medicare for All remains a disaster proposition
Medicare for All is poised for a comeback. Earlier this month, Rep. Pramila Jayapal (D-WA), the former head of the Congressional Progressive Caucus, released polling data showing strong support for the idea among Democrats. Jayapal’s renewed push for socialized medicine comes as many Democratic candidates for U.S. Senate are putting ...
Commentary
Terrible Effects of Medicare Price Controls Are Here
Medicare will impose price controls on prescription drugs for the first time when the calendar flips to January. Even before those controls formally take effect, the damage is already being done. The scheme has begun to hollow out America’s biomedical research ecosystem. Patients will pay the price — in the ...
Commentary
What America Needs from a GOP Healthcare Package
The U.S. House just passed legislation that will help make health insurance more affordable — without extending the enhanced premium subsidies for exchange coverage that Democrats enacted during the COVID-19 pandemic. The House action comes on the heels of votes on two measures in the Senate: one from Democrats that ...
Blog
Do price controls affect which drugs patients have access to and how soon?
Do price controls affect which drugs patients have access to and how soon? They absolutely do. Just look at the situation in Europe. For years, drug companies have been choosing to withhold certain medicines from European markets rather than accept the price constraints imposed by governments there. As a result, ...
New Issue Brief: Biopharma Drug Makers Are Not the Most Profitable Players in Health Care
A new issue brief released by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute finds that innovative drug manufacturers earn some of the lowest risk-adjusted returns in the U.S. health care system, despite making the largest investments in research and development. The findings challenge the ...
Enhanced Obamacare subsidies are gone. They deserve to stay that way
House Ways and Means Committee Chairman Jason Smith (R-MO) took to the chamber’s floor last week to voice his opposition to legislation that would extend the pandemic-era enhanced premium subsidies for Obamacare plans for three years. Unfortunately, his wise counsel fell on deaf ears, as all Democrats and 17 Republicans ...
PRI Files Amicus Brief in Major Supreme Court Case That Could Upend Future Medical Innovation Nationwide
SACRAMENTO – California-based free market think tank the Pacific Research Institute announced today that it has filed an amicus curiae brief urging the U.S. Supreme Court to hear two cases challenging the federal government’s new prescription drug pricing program enacted under the Inflation Reduction Act. The cases, Janssen Pharmaceuticals, Inc. ...
Congress Must Prioritize Patients, Not Insurers, In Renewed Healthcare Debate
Congress has returned to Washington. Democrats are renewing their call to extend COVID-era health insurance subsidies to shield people from hefty premium increases. Just last week, some Republicans in the House joined them to pass a bill that extends these subsidies—putting the question squarely before the Senate. That approach would ...
California should embrace competition to promote better health insurance
Following a depressingly familiar pattern, California is once again undermining health care competition in the vain hope that less competition will lead to lower prices. It won’t. In its latest anti-competitive actions, starting Jan. 1, California’s Department of Health Care Services will be limiting competition for plans (called Medi-Medi plans) ...
How can we make drugs more affordable without sacrificing future cures?
How can we make drugs more affordable without sacrificing future cures? To a large extent, the current system works fairly well already to make most of the drugs that Americans take affordable. And that’s because of our robust generics market. Around 90% of prescriptions filled each year are for generics ...
Medicare for All remains a disaster proposition
Medicare for All is poised for a comeback. Earlier this month, Rep. Pramila Jayapal (D-WA), the former head of the Congressional Progressive Caucus, released polling data showing strong support for the idea among Democrats. Jayapal’s renewed push for socialized medicine comes as many Democratic candidates for U.S. Senate are putting ...
Terrible Effects of Medicare Price Controls Are Here
Medicare will impose price controls on prescription drugs for the first time when the calendar flips to January. Even before those controls formally take effect, the damage is already being done. The scheme has begun to hollow out America’s biomedical research ecosystem. Patients will pay the price — in the ...
What America Needs from a GOP Healthcare Package
The U.S. House just passed legislation that will help make health insurance more affordable — without extending the enhanced premium subsidies for exchange coverage that Democrats enacted during the COVID-19 pandemic. The House action comes on the heels of votes on two measures in the Senate: one from Democrats that ...
Do price controls affect which drugs patients have access to and how soon?
Do price controls affect which drugs patients have access to and how soon? They absolutely do. Just look at the situation in Europe. For years, drug companies have been choosing to withhold certain medicines from European markets rather than accept the price constraints imposed by governments there. As a result, ...
